FTNW: JDRF IDDP with Amylin Pharmaceuticals

Good friend of the Blog Scott Strumello brought this to my attention. I think it is worthy of a From The New Wire post so thanks Scott for the heads up:

From Amylin's site:  

Clinical proof-of-concept study will also evaluate whether metreleptin can reduce the amount of insulin needed by patients with type 1 diabetes

NEW YORK and SAN DIEGO, Nov. 16, 2010 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

I wish JDRF were a little more forth coming in these releases like what level of funding is involved in the IDDP from Both the JDRF and Amylin. What are the milestones envisioned. Stuff like that. I would think that JDRF has a transparency responsibility to all those who support it and that Amylin would have similar a fiduciary information reporting roll. Well at least in the next 10K/Q presuming the matter is material and given it is worthy of a press release I assume it is material.